AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02593812 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stepping training
Description: Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
Study NCT00066469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
Study NCT00066469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
Study NCT00066469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
Study NCT00066469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
Study NCT04092907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9036 0.25% Ophthalmic Solution
Description: Ophthalmic Solution
Study NCT04092907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Ophthalmic Solution
Study NCT03292419 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Topography-guided LASIK
Description: LASIK surgery
Study NCT00837824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1.0 mg/kg every 2 weeks
Study NCT00837824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 3.0 mg/kg every 2 weeks
Study NCT01483534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLD Therapy (IPS SystemTM)
Description: Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC-DocGemzar adjuvant chemotherapy
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC-Doc adjuvant chemotherapy
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-Doc adjuvant chemotherapy
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid i.v. 2 years
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid i.v. 2 years
Study NCT02181101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid i.v. 5 years
Study NCT00762567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine HCl
Description: A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
Study NCT02723006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-580
Description: TAK-580 tablets
Study NCT02723006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-202
Description: TAK-202 infusion
Study NCT03195803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Stimulation
Description: All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
Study NCT03195803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
Study NCT01562379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice based complementary food supplement
Description: Locally developed rice based complementary food with and added vitamins and minerals.
Study NCT01562379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plumpy Doz
Description: Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
Study NCT04471532 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change intervention
Description: It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks.
Study NCT01814228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter ablation of ganglionated plexi in right atrium
Study NCT01023139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
Study NCT02621281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney Transporter machines
Description: Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
Study NCT02723006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: vedolizumab infusion
Study NCT02723006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab infusion
Study NCT02621281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold storage
Description: The kidneys procurement from the donor will be cold stored using some cold preservation solution.
Study NCT03139773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
Study NCT03139773 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
Study NCT04495322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.
Study NCT04495322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
Study NCT00906555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modification of hemodialysis parameters on dialysis machine
Description: Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
Study NCT02597348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
Study NCT00731289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
Study NCT04744766 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: major duct excision
Description: 2 methods of major/central mammary duct excision are compared as regard the outcome
Study NCT02112149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVESTRONG
Description: The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
Study NCT03153124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
Study NCT00779597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCION (Self care improvement through oncology nursing)-PAIN program
Description: The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
Study NCT02350192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-health educational intervention (eHEI)
Description: The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
Study NCT00443534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
Study NCT04475029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
Study NCT04475029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
Study NCT02723006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab infusion
Study NCT01711229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Ofirmev will be given 15 minutes prior to going to the OR
Study NCT01711229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen
Description: oral acetaminophen will be given preoperatively
Study NCT03350139 — intervention group
Intervention type: DEVICE
Intervention: gamma knife radiosurgery
Description: The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
Study NCT00439699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Mematine administration
Study NCT01448824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally
Study NCT04262557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sunrise® solution
Description: Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.
Study NCT04262557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Gold standard method to diagnose SAS used as comparator
Study NCT03481296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Control
Description: Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
Study NCT03481296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Adapted Decision Support Navigation Intervention
Description: Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
Study NCT02893332 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: SBRT
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
Study NCT01448824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT02893332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI (Gefitinib or Tarceva )
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
Study NCT02893332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI (Gefitinib or Tarceva )
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
Study NCT04429828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 e-package: Psychological wellbeing for healthcare workers
Description: All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.
Study NCT00957723 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon® CR Total Knee System
Description: The purpose is to evaluate the Triathlon® CR Total Knee System.
Study NCT00146224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa RB
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
Study NCT00146224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa DT
Description: Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
Study NCT00626795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD1414 2% cream
Description: BID 7 days
Study NCT00626795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD1414 2% cream
Description: TID 7 days
Study NCT01448824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Administered orally
Study NCT01370837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of Candida albicans antigen.
Description: Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
Study NCT01370837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement.
Description: Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
Study NCT00787930 — intervention group
Intervention type: DRUG
Intervention: Valproic Acid
Description: Tablets, 250mg-3000mg
Study NCT01696344 — intervention group
Intervention type: PROCEDURE
Intervention: PVAI
Study NCT01696344 — intervention group
Intervention type: PROCEDURE
Intervention: PVAI + ablation of extraPV triggers
Description: PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
Study NCT02666456 — intervention group
Intervention type: OTHER
Intervention: QST, Questionnaires
Description: Assessment of sensory phenotype by QST and questionnaires
Study NCT04492709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
Study NCT04492709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
Study NCT00958464 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
Study NCT03618628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Fiber Off Loading Orthosis (CFO)
Description: A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
Study NCT04150731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 16α-18F-fluor-17β-estradiol
Description: 16α-18F-fluor-17β-estradiol PET/CT scan
Study NCT00626795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactroban® (mupirocin) 2% cream
Description: BID 7 days
Study NCT02993783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion
Study NCT01984294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
Study NCT01984294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01984294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Description: GS-9669 tablet(s) administered orally once daily
Study NCT02630420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab and savolitinib
Description: Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
Study NCT01741532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
Study NCT01741532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A deferiprone matching placebo oral solution will be given twice daily for 18 months.
Study NCT05663827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.